Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

den Bent MJ, van; AF, Carpentier; AA, Brandes; M, Sanson; MJ, Taphoorn; HJ, Bernsen; M, Frenay; CC, Tijssen; W, Grisold; L, Sipos; H, Haaxma-Reiche; JM, Kros; Kouwenhoven MC, van; CJ, Vecht; A, Allgeier; D, Lacombe; T, Gorlia

doi:10.1200/jco.2005.04.6078

Public

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

Shared by NobleBlocks on Jun 1, 2006 • 12:00 AM UTC

Authors:

van den Bent MJ

Carpentier AF

Brandes AA

Abstract

Purpose Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas. We investigated, in a multicenter randomized controlled trial, whether adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy improves overall survival (OS) in newly diagnosed patien...

Discussions